Drug
Belrestotug clinical trials
Also written EOS884448 and GSK4428859A.
- studies test it
- 8
- open now
- 0
- in phase 3
- 1
- first study started
- 2019
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 0
GlaxoSmithKline (6) · iTeos Belgium SA (1) · iTeos Therapeutics (1)
Often tested with
Tested in the same studies.
Dostarlimab (6) · Nelistotug (5) · Remzistotug (2) · Risvutatug rezetecan (1) · Cobolimab (1) · Inupadenant (1) · Docetaxel (1) · Feladilimab (1)
Studies
Open first, then newest update. How each study uses belrestotug is read from its arms, and is right about nine times in ten.
Testing it · 8
- First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT05277051Written as Belrestotug
- A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202Active, not recruitingPhase 2GlaxoSmithKlineNCT06062420Written as Belrestotug
- A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)Active, not recruitingPhase 3GlaxoSmithKlineNCT06472076Written as Belrestotug
- A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung CancerActive, not recruitingPhase 2GlaxoSmithKlineNCT05565378Written as Belrestotug
- Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1GlaxoSmithKlineNCT04446351Written as Belrestotug
- Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedPhase 2GlaxoSmithKlineNCT03739710Written as GSK4428859A
- First-In-Human Study of EOS884448 in Participants with Advanced Cancers.CompletedPhase 1iTeos TherapeuticsNCT04335253Written as EOS884448
- Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid TumorsActive, not recruitingPhase 1/2iTeos Belgium SANCT05060432Written as EOS-448
Given in every arm · 1 — belrestotug is usual care beside what is tested
Codes
What other systems call belrestotug · ClinicalTrials.gg INT015045
- UNII (FDA) 59HAW3EQ4CBELRESTOTUGOne source FDA
- NCI Thesaurus C176746BelrestotugOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 59HAW3EQ4C | BELRESTOTUG | One source FDA |
| NCI Thesaurus | C176746 | Belrestotug | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.